Sunday 18 October 2026 Export RCKT’s income statement to Excel — free account

Rocket Pharmaceuticals, Inc.

In the quarter to June 2026, EPS grew 275.8%, free cash flow grew 19.2% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.18 0.18 −7.63%

Follow RCKT

Alert me

Market cap: $259.1M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.03

Total sells 0.86

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	—	—	—	—	—	—	—	—	—
Sell	4	—	—	6	—	—	8	—	—	6	1	—

Insider Ownership 8.14%

Capital & Financial Ratios $m

Market Cap 259.07

Revenue —

Net Income (17.25)

Free Cash Flow (170.39)

Net Debt (264.42)

Current Ratio 9.24

Debt/Equity 0.05

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.67

Past 5Y EPS Growth —

This Y EPS Growth 93.53%

Next Y EPS Growth (948.43%)

Next Y revenue growth —

Next 5Y EPS Growth 18.58%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 4.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	373	372	189	284
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	378	378	193	290

	2023	2024	2025	Q'26
Payables	46	38	27	28
ST’ Debt	—	—	—	—
Other	—	—	—	—
	49	41	30	31

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	9.80%	(11.25%)	(17.28%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(40)	—	—	—
’25	(56)	(49)	(50)	(35)	(190)
’24	(57)	(54)	(52)	(47)	(210)
’23	(58)	(51)	(57)	(29)	(195)
’22	(39)	(39)	(44)	(56)	(178)
’21	(24)	(39)	(27)	(31)	(121)
’20	(22)	(22)	(17)	(13)	(75)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(40)	—	—	—
’25	(56)	(49)	(50)	(35)	(190)
’24	(59)	(56)	(54)	(47)	(216)
’23	(61)	(55)	(62)	(34)	(211)
’22	(41)	(42)	(44)	(59)	(186)
’21	(25)	(40)	(32)	(33)	(129)
’20	(28)	(24)	(17)	(27)	(95)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.42)	1.08	—	—	—
’25	(0.56)	(0.62)	(0.45)	(0.38)	(2.01)
’24	(0.66)	(0.74)	(0.71)	(0.62)	(2.73)
’23	(0.73)	(0.82)	(0.75)	(0.64)	(2.92)
’22	(0.67)	(0.83)	(0.87)	(0.92)	(3.26)
’21	(0.65)	(0.55)	(0.79)	(0.69)	(2.67)
’20	(0.45)	(0.45)	(0.53)	(1.08)	(2.52)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	23.24	3.40	9.64	10.76	9.01	20.92	7.57	14.89	11.15	2.19	Analyst estimates 2026–2028 Powerpack
	High	47.55	15.20	25.96	27.59	63.99	67.48	24.18	32.53	31.47	13.35
People
People	Employees	24	20	33	57	91	151	240	268	299	202
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(8)	(20)	(75)	(77)	(140)	(169)	(222)	(246)	(259)	(223)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(8)	(20)	(75)	(77)	(140)	(169)	(222)	(246)	(259)	(223)
	Depreciation	0	0	0	0	7	5	6	7	9	11
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1.11)	(2.88)	(1.89)	(1.58)	(2.52)	(2.67)	(3.26)	(2.92)	(2.73)	(2.01)
	Cash flow	(0.81)	(2.35)	(1.37)	(1.32)	(1.35)	(1.92)	(2.61)	(2.32)	(2.21)	(1.71)
	Capex	(0.05)	(0.11)	(0.04)	(0.47)	(0.37)	(0.12)	(0.12)	(0.20)	(0.06)	0.00
	Free cash flow	(0.85)	(2.46)	(1.40)	(1.79)	(1.72)	(2.04)	(2.74)	(2.52)	(2.27)	(1.71)
	Book value	10.71	2.28	4.93	6.27	9.09	7.19	7.19	5.86	4.89	2.49
	Shares, m	7	7	39	49	55	63	68	84	95	111
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(6)	(16)	(54)	(65)	(75)	(121)	(178)	(195)	(210)	(190)
	Capex	0	(1)	(1)	(23)	(21)	(8)	(8)	(16)	(6)	0
	Free cash flow	(6)	(17)	(55)	(88)	(95)	(129)	(186)	(211)	(216)	(190)
Balance, $m
Balance, $m	Working capital	121	14	194	289	455	370	325	330	337	163
	Total debt	49	—	41	46	59	19	19	19	19	19
	Net debt	(78)	(18)	(164)	(258)	(424)	(370)	(337)	(354)	(353)	(170)
	Shareholders’ equity	73	16	194	307	504	455	490	493	463	277
Returns, %
Returns, %	ROA	(6.23)	(26.14)	(54.90)	(24.79)	(29.02)	(31.08)	(42.31)	(43.93)	(47.30)	(52.00)
	ROIC	0.00	0.00	(149.47)	(96.76)	(105.28)	(122.79)	(91.91)	(116.96)	(154.83)	(134.54)
	ROE	(8.32)	(82.92)	(88.66)	(30.83)	(34.46)	(35.29)	(46.98)	(50.01)	(54.14)	(60.27)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)	Compare
IKT Inhibikase Therapeutics, Inc.	$255.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%	Compare
LCTX Lineage Cell Therapeutics, Inc.	$250.5M	— (loss-making)	— (loss-making)	−61.34% (below 0%: shrinking)	n/m	−32.40% (below 0%: shrinking)	100.00%	(834.71%)	Compare
Median of peers	$262.3M	—	—	+42.60%	—	−34.06%	87.30%	(156.20%)

All 614 Biotechnology stocks →

Rocket Pharmaceuticals, Inc. (RCKT) key facts

Rocket Pharmaceuticals, Inc. (RCKT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RCKT traded at $2.18, a market capitalization of $259.1 million.
Return on equity was −60.3% and debt-to-equity 0.05.

Source: company filings (standardised) and stockrow calculations.